REVANCE THERAPEUTICS, INC.

Profile

Company Names

REVANCE THERAPEUTICS, INC.

Addresses

7555 GATEWAY BLVD., NEWARK, CA 94560

755 GATEWAY BLVD., NEWARK, CA 94560

Phone Numbers

510-742-3400

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$114,597,116.00

Number of Funding Rounds:

5
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
5
2013-10-08 
$10,000,000.00 
$30,000,000.00 
$20,000,000.00 
Equity, Debt 
4
2013-02-05 
$5,000,001.00 
$60,000,000.00 
$54,999,999.00 
Equity 
3
2011-09-20 
$0.00 
$1,200,000.00 
$1,200,000.00 
 
2
2011-01-24 
$63,360,183.00 
$63,360,183.00 
$0.00 
Equity, Debt 
1
2009-12-08 
$36,236,932.00 
$36,236,932.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
DANIEL 
L. 
BROWNE 
EXECUTIVE OFFICER, DIRECTOR
REVANCE THERAPEUTICS, INC.
L. 
DANIEL 
BROWNE 
EXECUTIVE OFFICER, DIRECTOR
REVANCE THERAPEUTICS, INC.
ROBERT 
 
BYRNES 
DIRECTOR
VANDOLAY INC   |  REVANCE THERAPEUTICS, INC.   |  ULTHERA INC   |  NOVELLUS RESEARCH SITES INC   |  HOMELAND HOLDCO, INC.   |  ALLEGRO OPHTHALMICS, LLC   |  HOMELAND HEALTHCARE, LLC   |  A1 HEALTH GROUP, LLC
RON 
 
EASTMAN 
DIRECTOR
CELL BIOSCIENCES INC   |  REVANCE THERAPEUTICS, INC.   |  ESSEX WOODLANDS FUND IX, L.P.   |  SUNEVA MEDICAL INC.   |  EW HEALTHCARE PARTNERS FUND 2, L.P.   |  EW HEALTHCARE PARTNERS FUND 2-A, L.P.   |  SUNEVA MEDICAL, INC.
RONALD 
 
EASTMAN 
DIRECTOR
REVANCE THERAPEUTICS, INC.   |  SUNEVA MEDICAL, INC.
PHYLLIS 
 
GARDNER 
DIRECTOR
REVANCE THERAPEUTICS, INC.
JIM 
 
GLASHEEN 
DIRECTOR
TRANSCEND MEDICAL INC   |  REVANCE THERAPEUTICS, INC.   |  INCLINE THERAPEUTICS, INC.   |  ELCELYX THERAPEUTICS, INC.   |  FORSIGHT VISION5, INC.   |  CLADE THERAPEUTICS, INC.
FRANK 
 
KUNG 
DIRECTOR
SAGENT HOLDING CO.   |  REVANCE THERAPEUTICS, INC.   |  NEXTWAVE PHARMACEUTICALS INC   |  VIVO VENTURES VII AFFILIATES FUND, L.P.   |  VIVO CAPITAL FUND VIII, L.P.   |  VIVO CAPITAL SURPLUS FUND VIII, L.P.   |  AMYRIS, INC.   |  VIVO OPPORTUNITY FUND, L.P.   |  VIVO CAPITAL FUND IX, L.P.   |  VIVO OPPORTUNITY CO-INVEST, L.P.   |  VIVO OPPORTUNITY CO-INVEST (W), L.P.   |  VIVO INNOVATION FUND II, L.P.   |  VIVO ASIA OPPORTUNITY FUND, L.P.   |  VIVO OPPORTUNITY CAYMAN FUND, L.P.   |  VIVO CAPITAL FUND X, L.P.
VICENTE 
 
TRELLES 
DIRECTOR
REVANCE THERAPEUTICS, INC.   |  VIBRYNT, INC
JONATHAN 
 
TUNNICLIFFE 
DIRECTOR
REVANCE THERAPEUTICS, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2013-10-23
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity, Debt 
2013-10-08 
2013-02-22
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2013-02-05 
2013-01-09
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2011-01-24 
2012-09-14
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2011-01-24 
2011-10-06
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2011-09-20 
2011-06-14
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2011-01-24 
2011-02-03
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2011-01-24 
2010-11-18
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2009-12-08 
2010-08-23
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2009-12-08 
2010-06-01
D/A
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2009-12-08 
2009-12-23
D
Link
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2009-12-08 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#